Jazz Pharmaceuticals (JAZZ) FY2021 results: revenue $3.1 billion, up 30.9% on the year
Jazz Pharmaceuticals plc (JAZZ) reported revenue of $3.1 billion for fiscal 2021, the year ended 31 December 2021, up 30.9% on the year before. Net income was -$330 million, and diluted earnings per share $-5.52. The figures are the company's own, from the 10-K it filed with the SEC on 1 March 2022.
Revenue
$3.1 billion
+30.9% on the year
FY2014FY2021
Operating margin
5.5%
16.0% a year earlier
FY2014FY2021
Net income
-$330 million
FY2014FY2021
Diluted EPS
-$5.52
FY2014FY2021
this yearthe year beforeHover a bar for its figure.
$ million except per share. Read moreFree cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are.
Cash flow
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Operating cash flow
779
900
776
-13.5%
Capital expenditure
27.6
15.0
40.1
+84.2%
Free cash flow
751
885
736
-15.1%
Free cash flow margin
24.3%
37.4%
34.1%
Cash from investing
-5,212
-1,008
-155
Cash from financing
3,971
528
-294
+651.9%
Depreciation and amortisation
26.7
18.7
15.3
+42.8%
Share-based compensation
189
121
111
+56.2%
Buybacks
0.0
147
301
Diluted shares, weighted
60m
57m
58m
+5.6%
Shares outstanding at period end
62m
56m
56m
+9.7%
Balance sheet
$ million
FY2021
FY2020
FY2019
On the year
Last 8 years
Shareholders' equity
3,965
3,660
3,111
+8.3%
Debt
6,050
2,095
1,607
+188.8%
Operating lease liabilities
87.2
140
151
-37.7%
Finance lease liabilities
6.3
0.0
n/a
Other liabilities
2,190
641
669
+241.5%
Total liabilities and equity
12,299
6,536
5,539
+88.2%
Fixed assets
n/a
128
132
Goodwill
1,828
958
920
+90.7%
Intangible assets
7,152
2,195
2,441
+225.8%
Securities held for sale or to maturity
591
2,133
1,077
-72.3%
Cash and equivalents
591
1,058
637
-44.1%
Receivables
563
396
356
+42.1%
Inventory
1,073
95.4
78.6
+1,024.5%
Other assets
500
n/a
n/a
Total assets
12,299
6,536
5,539
+88.2%
10-K for the year ended 31 December 2021, filed 1 March 2022: the filing.